FDA Approves Merck's KEYTRUDA® (pembrolizumab) Plus Chemotherapy as First-Line Treatment for Locally Advanced Unresectable or Metastatic HER2-Negative Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma -November 16, 2023 at 05:41 pm EST

Approval based on results from the Phase 3 KEYNOTE-859 trial, which demonstrated significant improvement in overall survival in these patients versus chemotherapy alone


Approval marks seventh...

Related Keywords

Canada ,United States , ,Statement Of Merck Co Inc ,Drug Administration ,Facebook ,Exchange Commission ,Youtube ,Patient Support Program ,Instagram ,Merck Access Program ,Twitter ,Linkedin ,Merck Patient Support Program ,Merck Co Inc ,Selected Important Safety ,Important Safety Information ,Fatal Immune Mediated Adverse ,Which Can Present With Diabetic ,Nervous System ,Connective Tissue ,Patients With Multiple ,Neck Squamous Cell ,Bacillus Calmette Guerin Unresponsive ,Mismatch Repair Deficient ,Mismatch Repair Deficient Colorectal ,Support Program ,Looking Statement ,Securities Litigation Reform Act ,Annual Report ,Markets ,